spacer
home > news > detailed info
INDUSTRY NEWS AND PRESS RELEASES

CHDI Foundation extends collaboration with IRBM to accelerate development of Huntington’s disease therapeutics


IRBM, a global contract research organization (CRO), has strengthened its position in neurodegenerative disease research following an extension of its long-standing collaboration with CHDI Foundation, a nonprofit biomedical research organization exclusively dedicated to collaboratively developing therapeutics that substantially improve the lives of those affected by Huntington’s disease (HD).

HD is a genetic neurodegenerative disease for which there are currently only very limited treatment options. The collaboration with CHDI demonstrates IRBM’s commitment and passion for developing novel therapeutic solutions for this devastating disease.

Since 2011, IRBM has worked closely with CHDI to investigate innovative therapeutic approaches based on a better understanding of the biology of the disease. This has included significant contributions by IRBM to HD-specific mechanistic and translational research, as well as tailored drug discovery solutions.

The extension of this collaboration builds on IRBM’s expertise in the biology of neurodegenerative diseases, its comprehensive screening capabilities and continued access to IRBM’s compound collection and peptide libraries. IRBM will also continue to leverage its significant experience in integrated neuroscience drug discovery with small molecules and biologics, including the development of clinically qualified diagnostic assays and the creation of predictive models for blood-brain barrier permeability.

Piero Di Lorenzo, President and Founder of IRBM, said: “We are proud to be involved with this world-leading initiative to improve the quality of life of patients fighting against this terrible disease. Together with CHDI we are fully committed to help them: they deserve nothing less than our daily dedication.”

Robi Blumenstein, President of CHDI Management, Inc., said: “We are delighted to extend CHDI’s collaboration with our colleagues at IRBM. They have made invaluable contributions to a number of our programs and offer important services to the entire HD drug development community.”
 
Print this page
Send to a friend
   
spacer
News and Press Releases

Mr Turhan Ozen Chief Cargo Officer at Turkish Airlines elected to the International Air Cargo Association (TIACA) Committee

Turhan Ozen, serving as Chief Cargo Officer at the global brand Turkish Airlines, was elected to the International Air Cargo Association (TIACA) Committee, the joint voice of the industry that aims to enhance the air cargo profile with intensive efforts towards the global standards.
More info >>


White Papers

Accelerate Your Database Lock Using Clean Patient Optics

Bioclinica

Because a key step towards database lock is obtaining clean data for all patients, the ability to verify that data are clean early accelerates the ability to lock the clinical database. This ultimately shortens the overall study timeline while ensuring the quality of your data. However, this can be challenging when manually reviewing study data, particularly with larger studies.
More info >>

Industry Events

DIA 2019 Global Annual Meeting

23-27 June 2019, San Diego Convention Center

DIA 2019 is more than just a meeting: it’s where brilliant minds come together to create solutions. Thousands of global innovators will convene to engage in discussions on today’s hottest topics in the life sciences field, propose ways to combat daily challenges, and network to create lasting connections.
More info >>

 
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement